2023
Biological treatment for bullous pemphigoid
Oren-Shabtai M, Mimouni D, Nosrati A, Atzmony L, Kaplan B, Barzilai A, Baum S. Biological treatment for bullous pemphigoid. Frontiers In Immunology 2023, 14: 1157250. PMID: 37180101, PMCID: PMC10172582, DOI: 10.3389/fimmu.2023.1157250.Peer-Reviewed Original ResearchMeSH KeywordsAdultHumansImmunosuppressive AgentsOmalizumabPemphigoid, BullousRituximabSkin Diseases, VesiculobullousConceptsBullous pemphigoidImmunosuppressive therapyPatients treated with rituximabLong-term corticosteroid useAdjuvant immunosuppressive therapyConventional immunosuppressive therapySteroid-sparing agentsAutoimmune subepidermal bullous diseaseFirst-line treatmentPrevious treatment failuresSeries of patientsFollow-up periodFollow-up visitSignificant side effectsNo adverse eventsSubepidermal bullous diseasesBP durationRecalcitrant BPRituximab coursesSystemic corticosteroidsClinical responseTreatment failureCorticosteroid useImmunobiological therapyBiologic therapy
2020
Treatment of Bullous Pemphigoid in People Aged 80 Years and Older: A Systematic Review of the Literature
Oren-Shabtai M, Kremer N, Lapidoth M, Sharon E, Atzmony L, Nosrati A, Hodak E, Mimouni D, Levi A. Treatment of Bullous Pemphigoid in People Aged 80 Years and Older: A Systematic Review of the Literature. Drugs & Aging 2020, 38: 125-136. PMID: 33230804, DOI: 10.1007/s40266-020-00823-5.Peer-Reviewed Original ResearchMeSH KeywordsAgedHumansNeoplasm Recurrence, LocalPemphigoid, BullousProspective StudiesQuality of LifeRetrospective StudiesUnited StatesConceptsOlder patientsBullous pemphigoidTopical corticosteroidsCohort studyTreatment of bullous pemphigoidSide effect profileRetrospective cohort studyNational Institutes of Health databaseProspective cohort studySystematic reviewBackgroundBullous pemphigoidRandomized controlled trialsSignificant adverse effectsPartial responseSystemic corticosteroidsCase seriesTherapeutic optionsPatient selectionTreatment modalitiesAdverse eventsOlder adultsConclusionsCurrent dataPrimary outcomeSecondary outcomesUS National Institutes
2017
Reply to: Comment on “Association of bullous pemphigoid with malignancy: A systematic review and meta-analysis”
Atzmony L, Mimouni I, Reiter O, Leshem Y, Taha O, Gdalevich M, Hodak E, Mimouni D. Reply to: Comment on “Association of bullous pemphigoid with malignancy: A systematic review and meta-analysis”. Journal Of The American Academy Of Dermatology 2017, 85: e345. PMID: 29246822, DOI: 10.1016/j.jaad.2017.12.014.Peer-Reviewed Original ResearchAssociation of bullous pemphigoid with malignancy: A systematic review and meta-analysis
Atzmony L, Mimouni I, Reiter O, Leshem Y, Taha O, Gdalevich M, Hodak E, Mimouni D. Association of bullous pemphigoid with malignancy: A systematic review and meta-analysis. Journal Of The American Academy Of Dermatology 2017, 77: 691-699. PMID: 28645646, DOI: 10.1016/j.jaad.2017.05.006.Peer-Reviewed Original ResearchMeSH KeywordsCase-Control StudiesCohort StudiesCross-Sectional StudiesHematologic NeoplasmsHumansNeoplasmsPemphigoid, BullousConceptsPooled analysis of case-control studiesAnalysis of cross-sectional studiesStudy designAnalysis of case-control studiesMeta-analysisEstimate pooled odds ratiosBullous pemphigoidCross-sectional studyPooled odds ratioCase-control studyAssociation of BPOverall cancerRandom-effects modelAssociation of bullous pemphigoidWell-designed studiesCase-controlOdds ratioCohort studySystematic reviewOverall malignancyAssociated with malignancyCochrane LibraryLarynx cancerPooled analysisEffects model